APPLIED BIOSYSTEMS-3730 DNA ANALYZER (48 capillary)

描述(由申请人提供)：德克萨斯大学M.D.安德森癌症中心的DNA分析核心设施(DAF)申请资金，用于购买3730 DNA遗传分析仪(48毛细管仪器)，以执行DNA测序、重测序、荧光片段分析和SNPlex分析(用于识别多态和序列变异)。DAF是CCSG支持的中央核心设施，为M.D.安德森44个部门的187名主要调查人员提供服务；74%拥有同行审查的补助金。当NIH调查人员不使用这些服务时，该机构的其他成员可以使用这些服务。1992年成立的DAF已成为M.D.安德森研究实验室的一个组成部分。该机构的成员开始严重依赖该设施提供快速准确的DNA服务，使研究人员能够更快地实现他们的研究目标。该设施目前由埃里卡·汤普森女士管理。汤普森女士在DNA分析方面有11年的经验，自2003年以来一直管理该设施。所要求的仪器将：1)提高测序吞吐量，在2.5小时内处理48个样本进行DNA测序，而3730分析仪将取代3100仪器，只处理16个样本；2)提供显著的成本节约，例如3100的运行成本，每个样本0.60美元，3730的0.10美元；3)允许使用最新的SNPlex技术，在一次运行中快速识别每个样本多达48个SNP基因类型。这是因为每个样本多重48个SNPs的能力在分析来自癌症患者的少量DNA时尤其重要，因为SNPlex每个基因只需要不到0.8 ng的基因组DNA。3730基因分析仪将使该设施能够满足对现有服务日益增长的需求，并允许以VariantSEQr和SNPlex的形式向M.D.安德森的NIH支持的研究人员提供最新技术。目前，该设施无法提供这些额外服务，因为3730 XL遗传分析仪仅用于DNA测序，其余3100台用于使用荧光片段分析技术对人和鼠样本进行基因分型。DAF支持了数百份出版物的完成，其中包括发表在《自然医学》、《自然遗传学》和《细胞》上的研究报告。购买3730将使工厂能够增加产量，减少周转时间，为PI提供使用最新技术(SNPlex和VariantSEQr)的机会，并降低试剂成本。该仪器还可作为3730XL仪器(96毛细管仪器)的备用仪器。M.D.安德森于2002年购买了3730XL，目前是该设施的主力，现已达到产能。DAF获得最先进的3730基因分析仪是至关重要的，这样核心才能继续为NIH资助的研究人员提供支持癌症研究的最新技术。

DESCRIPTION (provided by applicant): The DNA Analysis Core Facility (DAF) at the University of Texas M. D. Anderson Cancer Center requests funds for the purchase of a 3730 DNA Genetic Analyzer (48capillary instrument) to perform DNA sequencing, resequencing, fluorescent fragment analysis and SNPlex analysis (for identifying polymorphisms and sequence variants). The DAF is a CCSG supported centralized Core facility that provides services to 187 of principal investigators in 44 departments at M.D. Anderson; 74% hold peer-reviewed grants. When NIH investigators are not using these services, they are made available to other members of the institution. The DAF which opened in 1992 has become an integral part of the research laboratories at M.D. Anderson. Members of the institution have come to rely heavily on the facility to provide fast and accurate DNA services, allowing researchers to progress more rapidly with their research goals. The facility is currently supervised by Ms. Erika Thompson M.S. Ms. Thompson has 11 years experience in DNA analysis and has been managing the facility since 2003. The requested instrument will: 1) increase sequencing throughput, processing 48 samples in 2.5hour for DNA sequencing, versus only 16 samples on the 3100 instrument which the 3730 Analyzer will replace, 2) provide significant cost savings e.g. running costs on 3100, $0.60 per sample versus $0.10 on 3730, 3) permit the use of the latest SNPlex technology to rapidly identify up to 48 SNP genotypes per sample in one run. This is ability to multiplex 48 SNPs per sample is especially important in the analysis of small amounts of DNA from cancer patients as SNPlex requires less than 0.8ng of genomic DNA per genotype. The 3730 genetic analyzer will allow the facility to meet the growing demands for existing services and also allow the latest technology in the form of VariantSEQr and SNPlex to be made available to NIH supported investigators at M.D Anderson. At this time the facility cannot provide these additional services as the 3730 XL Genetic analyzer is being used solely for DNA sequencing and the remaining 3100 for genotyping human and mouse samples using fluorescent fragment analysis technology. The DAF has supported the completion of several hundred publications including studies reported in Nature Medicine, Nature Genetics, and Cell. The purchase of a 3730, would allow the facility to increase throughput, reduce turnaround time, provide PIs access to the latest technology (SNPlex and VariantSEQr) and reduce reagent cost. This instrument would also serve as a back up to the 3730XL instrument (the 96 capillary instrument). The 3730 XL, which was purchased by M.D. Anderson in 2002, is currently the workhorse of the facility, and is now reaching capacity. It is critical that the DAF obtain a state of the art, 3730 Genetic Analyzer, so that the core can continue to provide NIH funded investigators with the latest technology to support cancer research.